COMMUNIQUÉS West-GlobeNewswire

TerrAscend Reports Third Quarter 2024 Financial Results
06/11/2024
Net Revenue of $74.2 million and Gross Profit Margin of 48.8% 9 th consecutive quarter of positive Cash Flow from continuing operations and fifth consecutive quarter of positive Free Cash Flow 1 Closed on a senior [...]
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
06/11/2024
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of Dr [...]
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
06/11/2024
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - Duchenne: [...]
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
06/11/2024
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class [...]
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
06/11/2024
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + [...]
Spectral AI Announces 2024 Third Quarter Financial Results
06/11/2024
Revenue Rose to $8.2 Million Company Reaffirms Timeline for Regulatory Submission to U.S. FDA Q3 2024 Overview Research & Development Revenue Rose 138% to $8.2 Million Last Patient Out at Burn Centers for U.S. Burn [...]
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
06/11/2024
Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAK TM -1 Phase 1b/2 Trial of TN-201 Gene Therapy Initial TN-201 Data from Cohort 1 of MyPEAK-1 to be Reported in [...]
OraSure Reports Q3 ’24 Revenue of $39.9 Million
06/11/2024
Q3 GAAP EPS of $(0.06) ; Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics [...]
PetMeds® Announces Second Quarter Fiscal 2025 Financial Results
06/11/2024
DELRAY BEACH, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its second quarter ended September 30, 2024 [...]
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
06/11/2024
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and [...]
OrthoPediatrics Corp. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Revenue Guidance
06/11/2024
Record Third Quarter 2024 Revenue Increased 37% Year-over-Year WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on [...]
Seer Reports Third Quarter 2024 Financial Results
06/11/2024
Growing enthusiasm for Proteograph Product Suite with multiple larger orders from government agencies and continued strong interest in STAC REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: [...]
Inari Medical to Participate in the Jefferies London Healthcare Conference
06/11/2024
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other [...]
QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook
06/11/2024
Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 // Net sales of $502 million CER ahead of outlook for at least $495 million [...]
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
06/11/2024
Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, demonstrating clinical proof of concept Initiated a Phase 1 trial for PRT7732, its first-in-class [...]
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
06/11/2024
Third Quarter 2024 Total Revenues of $293.8 million, increase of 9% versus prior year Third Quarter 2024 Net Income of $114.8 million, increase of 144% versus prior year Third Quarter 2024 Adjusted EBITDA of $105.3 [...]
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
06/11/2024
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat [...]
Option Care Health to Participate in Upcoming Investor Conferences
06/11/2024
BANNOCKBURN, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
06/11/2024
FOSTER CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Pages